Edwards maintained its 2025 financial guidance, targeting total company sales of $5.6 billion to $6 billion, with TAVR sales of $4.1 billion to $4.4 billion, TMTT sales of $500 million to $530 million ...

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...

Pre-earnings options volume in Edwards Lifesciences (EW) is normal with calls leading puts 9:2. Implied volatility suggests the market is ...

Edwards Lifesciences Corp (NYSE:EW) reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $0.59 against a ...

Edwards Lifesciences (NYSE: EW) shares got a boost after hours today on fourth-quarter results that came in ahead of the consensus forecast.

For the quarter ended December 2024, Edwards Lifesciences (EW) reported revenue of $1.39 billion, down 9.7% over the same period last year. EPS came in at $0.59, compared to $0.64 in the year-ago ...

Company has N G Jain & Co. as its auditors. As on 31-03-2024, the company has a total of 2.38 Crore shares outstanding.Avon Lifesciences Share Price Today is Rs. 2.86. On previous day, the Avon ...